A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies

Clinical Cancer Research

Volumn 6, Issue 1, 2000, Pages 57-63

  Pinguet, Frédéric ^a   Culine, Stéphane ^a   Bressolle, Françoise ^a,b   Astre, Cécile ^a   Serre, Marie Pierre ^a   Chevillard, Claude ^c   Fabbro, Michel ^a  

^a Anticancer Center   (France)

^b UNIV MONTPELLIER   (France)

^c CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADOLESCENT; ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MELPHALAN; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; REGRESSION ANALYSIS; THROMBOCYTOPENIA;

EID: 0033978423     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Samuels, B., and Bitran, J. D. High-dose intravenous melphalan: a review. J. Clin. Oncol., 13: 1786-1799, 1995.
2. Sarosy, G., Leyland-Jones, B., Soochan, P., and Cheson, B. D. The systemic administration of intravenous melphalan. J. Clin. Oncol., 11: 1768-1782, 1988.
3. Tattersall, M. H., Jarman, N., Newlands, E. S., Holyhead, L., Milstead, R. A., and Weinberg, A. Pharmacokinetics of melphalan following oral or intravenous administration in patients with malignant disease. Eur. J. Cancer, 14: 507-513, 1978.
4. Thigpen, T., Vance, R., Puneky, L., and Khansur, T. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol. Oncol., 55: 97-107, 1994.
5. Ossenkoppele, G. J. Treatment of multiple myeloma in elderly patients. New developments. Drugs Aging, 11: 152-164, 1997.
6. Vogelzang, N. J. Continuous infusion chemotherapy: a critical review. J. Clin. Oncol., 2: 1289-1299, 1984.
7. Bosanquet, A. G., and Bird, M. C. Degradation of melphalan in vitro: rationale for the use of continuous exposure in chemosensitivity assays. Cancer Chemother. Pharmacol., 21: 211-215, 1988.
8. Teicher, B. A., Holden, S. A., Eder, J. P., Brann, T. W., Jones, S. M., and Frei, E. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Res., 49: 5994-5998, 1989.
9. Pinguet, F., Bressolle, F., Culine, S., Fabbro, M., Astre, C., and Chevillard, C. Influence of the schedule of administration on the cytotoxic effect of melphalan toward human 8226 and A2780 cells. Eur. J. Cancer, 35: 1402-1406, 1999.
10. Ardiet, C., Tranchand, B., Biron, P., Rebattu, P., and Philip, T. Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Cancer Chemother. Pharmacol., 16: 300-305, 1986.
11. Gouyette, A., Hartmann, O., and Pico, J. L. Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother. Pharmacol., 16: 184-189, 1986.
12. Tranchand, B., Ploin, Y. D., Minuit, M. P., Sapet, C., Biron, P., Philip, T., and Ardiet, C. High-dose melphalan dosage adjustment: possibility of using a test dose. Cancer Chemother. Pharmacol., 23: 95-100, 1989.
13. Ninane, J., Baurain, R., de Selys, A., Trouet, A., and Cornu, G. High dose melphalan in children with advanced malignant disease. Cancer Chemother. Pharmacol., 75: 263-267, 1985.
14. Bosanquet, A. G., and Gilby, E. D. Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur. J. Cancer Clin. Oncol., 18: 355-362, 1982.
15. Taha, A. K., Ahmad, R. A., Gray, H., Robert, C. I., and Rogers, H. J. Pharmacokinetics of melphalan in children following high-dose intravenous injection. Cancer Chemother. Pharmacol., 10: 212-216, 1983.
16. Hersh, M. B., Ludden, T. M., Kuhn, J. G., and Knight, W. A. Pharmacokinetics of high-dose melphalan. Invest. New Drugs, 1: 331-334, 1983.
17. Pinguet, F., Martel, P., Rouanet, P., Fabbro, M., and Astre, C. Effect of sodium chloride concentration and temperature on melphalan stability during storage and use. Am. J. Hosp. Pharm., 51: 2701-2704, 1994.
18. Cockcroft, D. W., and Gault, M. H. Prediction of creatinine clearance from serum creatinine. Nephron, 16: 31-47, 1976.
19. P-PHARM User's Guide, Ed. 3. Créteil, France: Centres d'Etudes el de Recherches en Statistiques et Informatique Medicales, 1994.
20. Pinguet, F., Joulia, J. M., Martel, P,. Grosse, P. Y., Astre, C., and Bressolle, F. High-performance liquid chromatographic assay for melphalan in human plasma. Application to pharmacokinetic studies. J. Chromatogr. B, 686: 43-49, 1996.
21. Rai, K. R., Holland, J. F., Glidewell, R. B., Weinberg, V., Brunner, K., Obrecht, J. P., Preisler, H. D., Nawabi, I. W., Prager, D., and Carey, R. W. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood, 58: 1203-1212, 1981.
22. Baker, L. H., Opipari, M. I., Wilson, H., Bottomley, R., and Coltman, C. A. Mitomycin C, vincristine, and bleomycin therapy for advanced cervical cancer. Obstet. Gynecol., 52: 146-150, 1978.
23. Fraschini, G., Yap, H. Y., Hortobagyi, G. N., Buzdar, A., and Blumenschein, G. Five-day continuous-infusion vinblastine in the treatment of breast cancer. Cancer (Phila.), 56: 225-229, 1985.
24. Lokich, J. J., Ahlgren, J. D., Gullo, J. J., Philips, D., and Fryler, J. G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J. Clin. Oncol., 7: 425-432, 1989.
25. Evans, W. E., Crom, W. R., Abromowitch, M., Dodger, R., Look, A. T., Bowman, W. P., Georges, S. L., and Pui, G. H. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia: identification of relation between concentration and effect. N. Engl. J. Med., 341: 471-477, 1986.
26. Mitchell, R. B., Ratain, M. J., and Vogelzang, N. J. Experimental rationale for continuous infusion chemotherapy. In: M. Rotman and C. J. Rosenthal (eds.), Concomitant Continuous Infusion Chemotherapy and Radiation, pp. 41-58. New York: Springer-Verlag, 1991.
27. Posner, M. R., Belliveau, J. F., Weitberg, A. B., Sabbath, K., Wiemann, M. C., Cummings, F. J., and Calabresi, P. Continuous infusion cisplatin and bolus 5 fluorouracil in colorectal carcinoma. Cancer Treat. Rep., 71: 975-977, 1987.
28. Samuels, B. L., Vogelzang, N. J., Ruane, M., and Simon, M. A. Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treat. Rep., 71: 971-972, 1987.
29. Jensen, J. L., Goel, R., and Venner, P. M. The effect of corticosteroid administration on bleomycin lung toxicity. Cancer (Phila.), 65: 1291-1297, 1990.
30. Barlogie, B., Jagannath, S., Epstein, J., Munshi, N., Siegel, D., Desikan, K. R., Feinman, R., Hsu, P. L., Von Bremen, K., and Tricot, G. Biology and therapy of multiple myeloma in 1996. Semin. Hematol., 34: 67-72, 1997.
31. Spitzer, G. Autotransplantation in solid tumors. Blood Rev., 5: 105-111, 1991.
32. Lokich, J. J. Alkylating agents with infusional schedules of delivery. J. Infusion Chemother., 1: 17-23, 1991.
33. Brox, L. W., Gowans, B., and Belch, A. L-phenylalanine mustard (melphalan) uptake and cross-linking in the RPMI 6410 human lymphoblastoid cell line. Cancer Res., 40: 1169-1172, 1980.
34. Ross, W. E., Ewig, R. A. G., and Kohn, K. W. Differences between melphalan and nitrogen mustard in the formulation and removal of DNA crosslinks, Cancer Res., 38: 1502-1506, 1978.
35. Loos, U., Musch, E., Engel, M., Hartlapp, J. H., Hugl, E., and Dengler, H. J. The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma. Eur. J. Clin. Pharmacol., 35: 187-193, 1988.
36. Alberts, D. S., Chang, S. Y., Chen, H-S. G., Evans, T. L., and Moon T. E. Oral melphalan kinetics. Clin. Pharmacol. Ther., 26: 737-745, 1979.
37. Woodhouse, K. W., Hamilton, P., Lennard, A., and Rawlins, M. D. The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen. Eur. J. Clin. Pharmacol., 24: 283-285, 1983.
38. Green, J. A., Vistica, D. T., Young, R. C., Hamilton, T. C., Rogan, A. M., and Ozols, R. F. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res., 44: 5427-5431, 1984.